Fig 1: The relationship between AI and the expression of TLR3 (a), TRIF (b), IRF3 (c), and NF-κB (d).
Fig 2: Immunohistochemical analysis of TLR3 expression and localization in HCC tissues. TLR3 was detected in the cytoplasm (a) and membrane (b). Magnification × 200.
Fig 3: The relationship between the number of EPCs and the expression of TLR3 (a), TRIF (b), IRF3 (c), and NF-κB (d).
Fig 4: Kaplan–Meier survival curves stratified according to the expression of TLR3 (a), TRIF (b), IRF3 (c), and NF-κB (d) (n = 76).
Fig 5: eRNA is involved in hypoxia induced expression of cTrop-T.ELISA estimation of circulating cTrop-T in plasma was done after (a) eRNA injection (80 μg/kg BW; 6 hrs prior to AH exposure) and RNaseA pre-treatment (1mg/kg BW; 2 hrs prior to AH exposure), (b) eDNA injection (80 μg/kg BW; 6 hrs prior to AH exposure) and DNase1 pre-treatment (5 mg/kg BW; 2 hrs prior to AH exposure), (c) HMGB1 IgG pre-treatment (200 μg/kg BW; 2 hrs prior to AH exposure), (d) pre-treatment with LTA (TLR2 agonist, 100 μg/kg BW; 2 hrs prior to AH exposure) and Poly I:C (TLR3 agonist, 1 mg/kg BW; 2 hrs prior to AH exposure). Control treatment with eRNA, eDNA, RNaseA, DNase 1, HMGB1 IgG, LTA and Poly I:C were done 6 hrs prior to sacrifice and the duration of AH exposure after different treatments was also 6 hrs. Data are shown as mean ± SEM (n = 5/group/treatment) from one experiment representative of three independent experiments, all performed in triplicate. One-way ANOVA revealed statistical significance in the results (*p< 0.05 groups w.r.t control; #p<0.05 groups w.r.t RNaseA).
Supplier Page from Abcam for Anti-TLR3 antibody [TLR3.7]